Skip to main content
. 2023 Jul 17;133(14):e158348. doi: 10.1172/JCI158348

Figure 3. Effect of anti–miR-93-5p therapy in the CLP-induced sepsis model.

Figure 3

(A) Twenty-four hours before CLP-induced sepsis, male and female C57BL/6 mice of different ages were treated i.p. with scrambled miRNA or anti–miR-93-5p. The treatment was repeated 2 hours after the induction of sepsis. Mice were followed up for 72 hours after CLP. (B) Plasma levels of miR-93-5p in septic mice treated with scrambled miRNA (n = 6) compared with septic mice treated with anti–miR-93-5p (n = 6). (C) Tissue levels of miR-93-5p in mice with sepsis treated with scrambled miRNA (n = 6) compared with septic mice treated with anti–miR-93-5p (n = 7) in organs frequently affected by sepsis: liver, heart, and kidney. (D) Pro- and antiinflammatory cytokine levels in anti–miR-93-5p–treated mice relative to levels in mice treated with scrambled miRNA. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01, and ****P < 0.0001, by 2-tailed Student’s t test (B–D). (E) Kaplan-Meier survival analysis for 4.5-month-old CLP-induced septic mice treated with scrambled miRNA (n = 6) versus CLP-induced septic mice treated with anti–miR-93-5p (n = 6). (F) Kaplan-Meier survival analysis for 8-month-old CLP-induced septic mice treated with scrambled miRNA (n = 6) versus CLP-induced septic mice treated with anti–miR-93-5p (n = 7). (G) Kaplan-Meier survival analysis for 16-month-old CLP-induced septic mice treated with scrambled miRNA (n = 6) versus CLP-induced septic mice treated with anti–miR-93-5p (n = 9). (H) Kaplan-Meier survival analysis for all CLP-induced septic mice treated with scrambled miRNA together (n = 18) versus all CLP-induced septic mice treated with anti–miR-93-5p together (n = 22).